Sponsors (6)
The bill expands controlled importation of prescription drugs to lower prices and increase short‑term access for many patients, but it raises trade-offs in safety risk if enforcement lapses, added regulatory and compliance costs, and potential long‑term effects on domestic pharmaceutical incentives.
Low- and middle-income patients and other people who struggle with high U.S. drug prices could pay less by importing lower-priced, approved prescription drugs from Canada, the UK, EU states, Switzerland, and other approved countries.
Patients who previously skipped or rationed prescriptions because of cost (especially those with chronic conditions) are more likely to fill and adhere to treatments, improving health outcomes.
Patients who need high-cost products—insulin, peritoneal dialysis solution, certain biologics, REMS drugs, and some IV drugs—could gain lower-cost access when those products are imported by authorized importers.
Patients and the broader U.S. drug supply could face safety risks—counterfeit, diverted, misbranded, or non‑FDA‑identical formulations—if importation channels or enforcement are not tightly maintained.
Taxpayers and/or manufacturers could bear increased regulatory and enforcement costs to run and police the importation program (FDA/HHS oversight, testing, reporting, suspension activities).
Pharmacies, wholesalers, importers, hospitals, and manufacturers will face greater administrative complexity and compliance burdens (certification, biannual reporting, special labeling, tracking), increasing operating costs and logistical difficulty.
Based on analysis of 3 sections of legislative text.
Requires HHS to issue regulations within one year to allow regulated importation of qualifying prescription drugs from specified foreign countries under federal oversight.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.
Introduced May 1, 2025 by Janice D. Schakowsky · Last progress May 1, 2025
Directs the Department of Health and Human Services to issue regulations within one year allowing the importation of certain safe, qualifying prescription drugs from specified foreign countries (including Canada, the UK, EU member states, and Switzerland) by certified foreign sellers, wholesale distributors, pharmacies, and individuals. It creates definitions and a regulatory framework for certification, lists categories of drugs that may be imported (including insulin and some biologics) while excluding controlled substances and certain other products, and requires HHS/FDA oversight to ensure safety and labeling requirements.